Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

STEMCELL Technologies Human Recombinant Flt3/Flk-2 Ligand, Size: 10 µg
SDP

Supplier:  STEMCELL Technologies 78009.1

Encompass_Preferred

Modulate the proliferation, differentiation and survival of hematopoietic stem and progenitor cells with Flt3/Flk-2 Ligand (Hannum et al. Nature, 1994). Flt3/Flk-2 Ligand, in combination with stem cell factor and thrombopoietin, can promote the expansion of primitive CD34+ hematopoietic cells in culture (Hannum et al.). Together with different interleukins and cytokines, Flt3/Flk-2 Ligand can also be used to regulate the development of various lymphoid progenitor cells, including dendritic cell, B cell, T cell, and NK cell progenitors. While Flt3/Flk-2 Ligand is produced by a variety of cell types, the expression of its receptor is restricted to CD34+ hematopoietic stem and progenitor cells (Drexler & Quentmeier. Growth Factors, 2004). Human recombinant Flt3/Flk-2 Ligand from STEMCELL comes lyophilized with ≥ 95% purity; specific activity EC50 ≤ 10 ng/mL; endotoxin levels verified ≤ 1 EU/μg protein. Alternative names: FL, FLT3L, Flt3-L, Flt3 Ligand, Fms-like tyrosine kinase 3 ligand.

Catalog No. NC1229312


May include imposed supplier surcharges.
Only null left
Add to Cart

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.